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Abstract 
Background: Multi-drug resistance (MDR) and extensive-drug resistance (XDR) associated with extended-spectrum 
beta-lactamases (ESBLs) and carbapenemases in Gram-negative bacteria are global public health concerns. Data on 
circulating antimicrobial resistance (AMR) genes in Gram-negative bacteria and their correlation with MDR and ESBL 
phenotypes from Nepal is scarce.
Methods: A retrospective study was performed investigating the distribution of ESBL and carbapenemase genes and 
their potential association with ESBL and MDR phenotypes in E. coli, Klebsiella spp., Enterobacter spp. and Acinetobacter 
spp. isolated in a major tertiary hospital in Kathmandu, Nepal, between 2012 and 2018.
Results: During this period, the hospital isolated 719 E. coli, 532 Klebsiella spp., 520 Enterobacter spp. and 382 Acine-
tobacter spp.; 1955/2153 (90.1%) of isolates were MDR and half (1080/2153) were ESBL producers. Upon PCR ampli-
fication, blaTEM (1281/1771; 72%), blaCTXM-1 (930/1771; 53%) and blaCTXM-8 (419/1771; 24%) were the most prevalent 
ESBL genes in the enteric bacilli. BlaOXA and blaOXA-51 were the most common blaOXA family genes in the enteric bacilli 
(918/1771; 25%) and Acinetobacter spp. (218/382; 57%) respectively. Sixteen percent (342/2153) of all isolates and 
20% (357/1771) of enteric bacilli harboured blaNDM-1 and blaKPC carbapenemase genes respectively. Of enteric bacilli, 
Enterobacter spp. was the most frequently positive for blaKPC gene (201/337; 60%). The presence of each blaCTX-M and 
blaOXA were significantly associated with non-susceptibility to third generation cephalosporins (OR 14.7, p < 0.001 and 
OR 2.3, p < 0.05, respectively).The presence of each blaTEM, blaCTXM and blaOXA family genes were significantly associ-
ated with ESBL positivity (OR 2.96, p < 0.001; OR 14.2, p < 0.001 and OR 1.3, p < 0.05 respectively) and being MDR (OR 
1.96, p < 0.001; OR 5.9, p < 0.001 and OR 2.3, p < 0.001 respectively).
Conclusions: This study documents an alarming level of AMR with high prevalence of MDR ESBL- and carbap-
enemase-positive ESKAPE microorganisms in our clinical setting. These data suggest a scenario where the clinical 
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Background
Gram-negative bacilli, particularly those in the bacterial 
family Enterobacteriaceae (e.g. Klebsiella spp. and Enter-
obacter spp.) and Acinetobacter spp. are common causes 
of serious community and hospital-acquired infections. 
These Gram-negative bacilli are also members of the 
ESKAPE group of pathogens [1].These are notoriously 
associated with antimicrobial resistance (AMR) and fre-
quently carry genes that induce resistance to three or 
more classes of antimicrobials, making them multi-drug 
resistant. Such multi-drug resistant Gram-negative bacilli 
represent a significant global public health problem as 
they are more commonly associated with worse out-
comes than susceptible isolates [2–5].The situation with 
multi-drug resistant Gram-negative bacilli is particularly 
alarming in South Asia, which is considered as a global 
epicentre of these microorganisms [6, 7].
Extended-spectrum beta-lactamases (ESBLs) are 
enzymes that can hydrolyse and therefore inactivate beta-
lactam antimicrobials such as penicillins, cephalosporins 
and monobactams. ESBL activity is an important mecha-
nism by which Gram-negative bacilli exhibit resistance 
against beta-lactam antimicrobials. Multiple ESBL vari-
ants have been detected and grouped into several struc-
tural and evolutionary families which include TEM, SHV, 
CTX-M, PER, VEB, GES, BES, TLA and OXA [8]. Of 
these, CTX-M and TEM are the most common ESBLs, 
while OXA enzymes such as OXA-48, 23, 24, 51, 58 are 
common carbapenemases that are associated with Gram-
negative bacteria that cause nosocomial infections [8, 9].
The possession of ESBLs increases the risk of treat-
ment failure with beta-lactam antimicrobials, may con-
tribute to the spread of AMR in Gram-negative bacteria 
and may complicate infection control in hospital [9, 10]. 
Therefore, detection and reporting for the presence of 
ESBLs in bacterial pathogens are important for clinical 
care. This is also essential for developing optimal infec-
tion control measures in hospital [10]. Modified disc dif-
fusion tests are routinely used to detect the presence of 
ESBLs and establish the nature of ESBL phenotypes [11]. 
Though being useful, these phenotypic detection meth-
ods are labour intensive and do not determine the classes 
of genes that are associated with ESBL activity. Molecu-
lar methods like PCR, DNA hybridization, or whole 
genome sequencing (WGS) may be used alongside phe-
notypic test methods to detect the presence of ESBL and 
carbapenemase associated genes and generate additional 
information regarding the epidemiological distribution of 
key resistance genes in sentinel locations [10].
South Asia is a key location for antimicrobial resistant 
pathogens. A high prevalence of MDR and ESBL posi-
tive Enterobacteriaceae family bacteria and Acinetobacter 
have been reported across the region [12–19]. However, 
little is known about various ESBL and carbapenemase 
genes associated with these phenotypes in Gram-neg-
ative bacilli isolated in hospitals of Nepal. Furthermore, 
there are little data originating from this region on the 
association of these genotypes with the observed phe-
notypes. Such data are important for assessing the con-
tribution of combined phenotypic and genetic tests on 
clinical care and providing better understanding of the 
impact of resistance genes on the epidemiology of circu-
lating pathogens.
Here, aiming to better understand the epidemiology 
of multi-drug resistant microorganisms and improve 
clinical care in our healthcare facility, we determined 
the AMR profile of all E. coli, Klebsiella spp., Entero-
bacter spp. and Acinetobacter spp. isolated from in- and 
out-patients at a major tertiary hospital in Kathmandu, 
Nepal, between June 2012 and December 2018. We addi-
tionally screened them for the phenotypic presence of 
ESBL activity by disc diffusion method and performed 
PCR amplification to detect any ESBL and carbapene-
mase associated AMR genes. Lastly, we investigated the 
relationship between the presence of blaCTX-M, blaTEM 
and blaOXA genes with an ESBL or MDR phenotype. 
Understanding the association between AMR genotype 
and phenotype is crucial to assess the value of genetic 
detection methods in clinical settings.
Methods
Study design
This was a retrospective study of anonymised routine 
microbiology laboratory results originating from Patan 
Hospital in Lalitpur metropolitan city of the Kathmandu 
Valley, Nepal. All data regarding E. coli, Klebsiella spp., 
Enterobacter spp. and Acinetobacter spp. that were iso-
lated from June 2012 to December 2018 were included in 
this study. These data were devoid of any personal iden-
tification information as this work was performed as a 
component of routine surveillance for infection control 
at Patan Hospital.
management of infected patients is increasingly difficult and requires the use of last-resort antimicrobials, which in 
turn is likely to intensify the magnitude of global AMR crisis.
Keyword: Multi-drug resistance, Antimicrobial resistance, Nepal, ESBL, Gram-negative bacilli, Carbapenemase, 
ESKAPE
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Antimicrobial susceptibility testing
Antimicrobial susceptibility testing was performed at the 
time of bacterial isolation by modified Kirby-Bauer disc 
diffusion method, as previously described [20]. Zone size 
interpretations were performed following the appropri-
ate Clinical and Laboratory Standards Institute (CLSI) 
guidelines [21]. The antimicrobials against which organ-
isms were tested are listed in Additional file 1: Table S1; 
not all isolates were tested for all antimicrobials.
The bacteria producing resistant or intermediate 
response against tested antimicrobials were grouped 
as “non-susceptible” for the purposes of analysis. MDR 
was defined as an acquired non-susceptibility (without 
intrinsic resistance) to at least one agent of three or more 
antimicrobial classes. Intrinsic resistance was defined 
according to the CLSI guideline of 2014 [21]. The follow-
ing intrinsic resistance were reported but ignored for the 
purpose of generating MDR profiles: (i) Acinetobacter 
spp. resistant against amoxicillin or penicillin, (ii) E. coli, 
Klebsiella, Enterobacter, or Acinetobacter spp. against 
vancomycin, teicoplanin, erythromycin or azithromycin. 
Phenotypic testing for ESBL positivity was conducted 
using the combination disc diffusion method with a beta-
lactam antimicrobial disc alone and that in combination 
with a beta-lactamase inhibitor (clavulanic acid) [22]. 
The isolate was considered as ESBL positive if the zone 
of inhibition around the beta-lactamase inhibitor supple-
mented disc was ≥ 5 mm in comparison to the respective 
beta-lactam antimicrobial alone. The products of Mast 
diagnostics (Mast group Ltd., Liverpool, UK) namely 
D62C and D68C were used in this study.
Detection of resistance genes
Bacterial DNA was extracted by suspending bacterial 
colonies in Phosphate buffered saline (PBS) and subject-
ing them to 100 °C for five minutes; the suspensions were 
centrifuged and the supernatant was used as template for 
PCR amplifications. The PCR amplifications were per-
formed in multiplex following previously described prim-
ers and conditions. The ESBL targets were blaCTXM-1, 
blaCTXM-2, blaCTXM-8, blaCTXM-9, blaCTXM-25, blaTEM and 
blaSHV [23]. The carbapenem resistance genes tested were 
blaOXA, blaKPC, blaOXA48 [24], blaNDM-1 [25], blaOXA1_4_30, 
blaOXA23, blaOXA24, blaOXA51, blaOXA58 [26], blaVIM and 
blaIMP [27].
For analysis purpose, the detection of any of blaOXA, 
blaOXA1_4_30, blaOXA23, blaOXA24, blaOXA48, blaOXA51 or 
blaOXA58 was designated as blaOXA positive. Similarly, 
the detection of any of blaCTXM-1, blaCTXM-2, blaCTXM-8, 
blaCTXM-9 or blaCTXM-25 was designated as blaCTXM pos-
itive. Fisher’s exact test was used to test for an associa-
tion between the detection of a resistance gene and a 
specific resistance phenotype (ESBL positive, MDR, or 
resistance to third and fourth generation cephalospor-
ins). All analyses were performed using the statistical 
software R version 3.5.3 and R Studio version 1.0.143. 
Venn diagrams were generated using the UpSetR R 
package [28].
Results
Bacterial isolates
Between June 2012 and December 2018, the microbiol-
ogy laboratory at Patan hospital isolated 719 E. coli, 532 
Klebsiella spp., 520 Enterobacter spp. and 383 Acineto-
bacter spp., totalling 2153 isolates (Table  1). A majority 
(512/2153; 23.8%) of isolates originated from the sam-
ples that were taken from the patients visiting emergency 
department followed by paediatric intensive care unit 
(PICU, 295/2153; 13.7%), gynaecology ward (287/2153; 
13.3%) and general medical ward (208/2153; 9.7%). The 
distribution of ESBL-positivity and MDR in microor-
ganisms by hospital departments is shown in Fig. 1. Half 
(1080/2153; 50.2%) of all bacterial isolates were ESBL 
positive (Table  2), which was predictably more com-
mon (> 50%) in E. coli, Klebsiella spp. and Enterobacter 
spp. isolates than in Acinetobacter spp. isolates (< 1%). 
Approximately 90% of E. coli, Klebsiella spp. and Entero-
bacter spp. were multi-drug resistant; this proportion 
was relatively lower in Acinetobacter spp. (82%).
Table 1 Summary of microorganisms
n %
Microorganisms (Total = 2153)
 E. coli 719 33.4
 Klebsiella spp. 532 24.7
 Enterobacter spp. 520 24.2
 Acinetobacter spp. 382 17.7
Departments (Total = 2153)
 Emergency 512 23.8
 Paediatric ICU 295 13.7
 Gynaecology 287 13.3
 Medical 208 9.7
 Adult ICU 154 7.2
 Nursery 136 6.3
 Surgery 116 5.4
 Paediatric 125 5.8
 Not known 219 10.2
 Outpatient 82 3.8
 Orthopaedic 19 0.9
ESBL positive (Total = 2153)
 No 1073 49.8
 Yes 1080 50.2
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The distribution of AMR genes
The presence of screened AMR genes, stratified by the 
number of microorganisms tested is presented in Table 3. 
In E. coli isolates, 90.1% (648/719) were positive for 
blaTEM, 58.0% (417/719) were positive for blaCTXM-8 and 
37.4% (269/719) were positive for blaOXA. In the Entero-
bacter spp., 56.2% (292/520) were positive for blaOXA, 
59.6% (201/520) were positive for blaKPC, 80.3% (417/520) 
were positive for blaCTXM-1 and 57.9% (301/520) were 
positive for blaTEM. In Klebsiella spp., 77.4% (408/532) 
were positive for blaCTXM-1, 67.2% (357/532) were posi-
tive for blaOXA, 4.1% (22/532) were positive for blaKPC 
and 62.5% (332/532) of tested isolates were positive for 
blaTEM. In Acinetobacter spp., 58.6% (218/382) were 
positive for blaOXA51, 36.0% (134/382) were positive for 
blaOXA23 and 20.7% (79/382) were positive for blaNDM-1.
The association of ESBL genes with ESBL phenotypes
For all subsequent analysis, isolates were classified as 
blaOXA or blaCTXM positive if any gene in the blaOXA or 
blaCTXM gene families were detected respectively. First, 
we assessed the association between phenotypic ESBL 
positivity and the presence of blaOXA, blaCTXM, and 
blaTEM (Table  4). The detection of each of these genes 
was significantly associated with an ESBL phenotype. The 
strength of association was variable between different 
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Fig. 1 ESBL and MDR positivity status of isolates by ward. Count of ESBL-positive and -negative (a) and MDR and non-MDR isolates (b) stratified by 
hospital wards from where the samples were taken
Table 2 ESBL positivity and MDR phenotype stratified by microorganisms
Microorganisms (N = 2153) ESBL-neg ESBL-pos Non-MDR MDR
n % n % n % n %
 E. coli (N = 719) 294 40.9 425 59.1 76 10.6 643 89.4
 Klebsiella spp. (N = 532) 210 39.5 322 60.5 44 8.3 488 91.7
 Enterobacter spp. (N = 520) 189 36.3 331 63.7 10 1.9 510 98.1
 Acinetobacter spp. (N = 382) 380 99.5 2 0.5 68 17.8 314 82.2
Page 5 of 13Manandhar et al. Ann Clin Microbiol Antimicrob           (2020) 19:48  
Table 3 Summary of detection of AMR genes
a Percentage of positive or negative in all isolates tested for a particular gene
b Not tested
Organisms Genes CTX-M1 CTX-M2 CTX-M8 CTX-M9 CTX-M25
n %a n %a n %a n %a n %a
E. coli neg 612 85.4 717 100 302 42.0 714 99.3 710 98.7
pos 105 14.6 0 0 417 58.0 5 0.7 9 1.3
n.t.b 2 2 0 0 0
Enterobacter neg 102 19.7 0 n.a 0 n.a 518 99.8 0 n.a
pos 417 80.3 0 n.a 0 n.a 1 0.2 0 n.a
n.t.b 1 520 520 1 520
Klebsiella neg 119 22.6 527 100 525 99.6 524 99.4 521 98.9
pos 408 77.4 0 0 2 0.4 3 0.6 6 1.1
n.t.b 5 5 5 5 5
Acinetobacter neg 368 98.9 372 100 372 100 372 100.0 372 100
pos 4 1.1 0 0 0 0 0 0.0 0 0
n.t.b 10 10 10 10 10
Organisms Genes OXA OXA1_4_30 OXA23 OXA24 OXA48 OXA51 OXA58
n %a n %a n %a n %a n %a n %a n %a
E. coli neg 450 62.6 0 n.a 0 n.a 0 n.a 715 99.4 0 n.a 0 n.a
pos 269 37.4 0 n.a 0 n.a 0 n.a 4 0.6 0 n.a 0 n.a
n.t.b 0 719 719 719 0 719 719
Enterobacter neg 228 43.8 0 n.a 0 n.a 0 n.a 221 65.6 0 n.a 0 n.a
pos 292 56.2 0 n.a 0 n.a 0 n.a 116 34.4 0 n.a 0 n.a
n.t.b 0 520 520 520 520 520
Klebsiella neg 174 32.8 0 n.a 0 n.a 0 n.a 475 89.5 0 n.a 0 n.a
pos 357 67.2 0 n.a 0 n.a 0 n.a 56 10.5 0 n.a 0 n.a
n.t.b 1 532 532 532 1 532 532
Acinetobacter neg 0 n.a 342 91.9 238 64.0 363 97.6 0 n.a 154 41.4 357 96.0
pos 0 n.a 30 8.1 134 36.0 9 2.4 0 n.a 218 58.6 15 4.0
n.t.b 382 10 10 10 382 10 10
Organisms Genes IMP KPC NDM1 SHV TEM VIM
n %a n %a n %a n %a n %a n %a
E. coli neg 577 99.7 719 100 681 94.7 719 100 71 9.9 578 99.8
pos 2 0.3 0 0.0 38 5.3 0 648 90.1 1 0.2
n.t.b 140 0 0 0 0 140
Enterobacter neg 90 100 136 40.4 412 79.2 515 99.0 219 42.1 90 100
pos 0 0 201 59.6 108 20.8 5 1.0 301 57.9 0 0.0
n.t.b 183 183 0 0 0 430
Klebsiella neg 100 100 509 95.9 414 78.0 415 78.2 199 37.5 100 100
pos 0 0 22 4.1 117 22.0 116 21.8 332 62.5 0 0.0
n.t.b 1 1 1 1 432
Acinetobacter neg 0 n.a 0 n.a 303 79.3 361 97.0 300 78.5 0 n.a
pos 0 n.a 0 n.a 79 20.7 11 3.0 82 21.5 0 n.a
n.t.b 382 382 90 10 90 382
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classes with an odds ratio (OR) of 1.3 (95% CI 1.1–1.5, 
p < 0.05) for blaOXA, 2.96 (95% CI 2.5–3.6, p < 0.001) for 
blaTEM and 14.2 (95% CI 11.2–18.1, p < 0.001) for blaCTXM 
in Fisher’s test.
Next, the association between ESBL positivity and 
various combinations of blaOXA, blaCTXM and blaTEM 
resistance genes were investigated. The isolates that 
were tested for at least one member of blaOXA fam-
ily, one member of blaCTXM family and blaTEM were 
analysed. A distribution of different combinations 
of blaOXA, blaCTXM and blaTEM resistance genes with 
ESBL positivity is shown in Fig.  2. The most frequent 
(485/1955; 24.8%) combination of genes that was asso-
ciated with ESBL positivity was at least one mem-
ber of blaOXA family gene, with at least a member of 
blaCTXM family gene and blaTEM gene. A smaller pro-
portion of isolates (176/1955; 9.0%) was PCR positive 
for blaOXA, blaCTXM and blaTEM, but was phenotypically 
ESBL negative. The second most common (242/1955; 
12.3%) gene combination associated with ESBL posi-
tivity was blaCTXM with blaTEM. The proportion of iso-
lates that were phenotypically ESBL positive, but PCR 
Table 4 Association between  ESBL positivity, MDR or  non-susceptibility to  cephalosporins and  presence of  resistance 
genes
Cephal. 3/4, 3rd or 4th generation cephalosporin
a An isolate was classified as blaOXA positive if blaOXA1_4_30, blaOXA, blaOXA-23, blaOXA-24, blaOXA-48, blaOXA-51 or blaOXA-58 was detected
b An isolate was classified as blaCTXM positive if blaCTXM-1, blaCTXM-2, blaCTXM-8, blaCTXM-9 or blaCTXM-25 was detected
c Odds ratio (OR and 95% CI) of bacterial isolate to be ESBL positive, multi-drug resistant or resistant to 3rd or 4th generation cephalosporin in the presence of a 
respective gene (gene family)
d p-value from Fisher’s exact test
Genes ESBL non-ESBL OR (95% CI)c p-valued
blaOXA
a
 OXA-neg 406 458
 OXA-pos 674 604 1.3 (1.1–1.5) 0.009
blaCTXM
b
 CTXM-neg 112 660
 CTXM-pos 968 401 14.2 (11.2–18.1) < 0.001
blaTEM
 TEM-neg 262 517
 TEM-pos 818 545 3.0 (2.5–3.6) < 0.001
Genes MDR non-MDR OR (95% CI)c p-valued
blaOXA
a
 OXA-neg 751 113
 OXA-pos 1198 80 2.3( 1.7–3.1) < 0.001
blaCTXM
b
 CTXM-neg 629 143
 CTXM-pos 1319 50 6.0 ( 4.2–8.6) < 0.001
blaTEM
 TEM-neg 680 99
 TEM-pos 1269 94 2.0 ( 1.4–2.7) < 0.001
Genes Cephal. ¾ non-susceptible Cephal. ¾ susceptible OR (95% CI)c p-valued
blaOXA
a
 OXA-neg 825 35
 OXA-pos 1244 26 2.0 ( 1.2–3.5) 0.008
blaCTXM
b
 CTXM-neg 710 54
 CTXM-pos 1358 7 14.7 ( 6.6–38.6) < 0.001
blaTEM
 TEM-neg 746 27
 TEM-pos 1323 34 1.4 (0.8–2.4) 0.22
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amplification negative for blaOXA, blaCTXM and blaTEM 
was 0.7% (14/1955).
The association of ESBL genes with non-susceptibility 
to third and fourth generation cephalosporins
We also tested for the association between non-suscep-
tibility to third and fourth generation cephalosporins 
(Cefotaxime, Cefepime, Ceftriaxone and Cefixime) and 
the presence of blaOXA, blaCTXM, or blaTEM (Table  4). 
The blaCTXM and blaOXA gene families were significantly 
associated with non-susceptibility to third and fourth 
generation cephalosporins with odds ratios of 14.7 (95% 
CI 6.6–38.6, p < 0.001) and 2.03 (95% CI 1.2–3.5, p < 0.05) 
respectively. The most frequent combination (654/2121; 
30.8%) associated with non-susceptibility against third 
and fourth generation cephalosporins was the presence 
of all three blaOXA, blaCTXM, and blaTEM genes, followed 
by the presence of blaCTXM and blaTEM only (357/2121; 
16.8%). Only 8.9% (189/2121) of isolates that were phe-
notypically non-susceptible to third and fourth genera-
tion cephalosporins were PCR amplification negative for 
blaOXA, blaCTXM, and blaTEM (Fig. 3).
The association of ESBL genes with MDR
We similarly investigated for any potential association 
between the presence of blaOXA, blaCTXM or blaTEM genes 
with MDR (Table  4). A multi-drug resistant phenotype 
was significantly associated with the presence of blaCTXM 
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Fig. 2 Association between ESBL positivity and combinations of resistance genes blaOXA, blaCTXM and blaTEM. Black circles represent ESBL positive 
and/or the detection of resistance genes of blaOXA family, blaCTXM family or blaTEM. A grey circle indicates that a characteristic was not detected. 
The vertical bars indicate the number of isolates in the group summarized directly below. The horizontal bars indicate the total number of isolates 
positive for resistance genes of blaOXA family, blaCTXM family, blaTEM or for ESBL positivity. An isolate was classified as blaOXA positive if any gene of 
blaOXA family was detected. The same is true for blaCTXM genes. Only the isolates that were tested for ESBL positivity, at least one member of blaOXA 
family, at least one member of blaCTXM family and blaTEM were included
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(OR 5.99, 95% CI 4.2–8.6, p < 0.001), blaOXA (OR 2.3, 
95% CI 1.7–3.1, p < 0.001) and blaTEM (OR 1.96, 95% CI 
1.4–2.7, p < 0.001). Additionally, the most common gene 
combinations associated with MDR were blaOXA and 
blaCTXM with blaTEM genes (648/2097; 30.9%), followed 
by blaCTXM with blaTEM (338/2097; 16.1%). A small frac-
tion of isolates (156/2097; 7.4%) were PCR amplification 
negative for blaOXA, blaCTXM and blaTEM, but were multi-
drug resistant phenotypes (Fig. 4).
As MDR was defined as an acquired non-suscepti-
bility to at least one agent in three different classes of 
antimicrobials, a multi-drug resistant phenotype can 
originate from a multitude of individual antimicrobial 
resistant phenotypes. Therefore, we compared the 
pattern of resistance for the isolates originating from 
outpatients (emergency ward and outpatient depart-
ment, Fig. 5a) and that from inpatients (all other wards, 
Fig.  5b). For the microorganisms originating from the 
outpatients, the three most frequent AMR combina-
tions accounted for over half (322/535; 60.2%) of all 
outpatient isolates. For the microorganisms originat-
ing from the inpatients, the three most frequent AMR 
combinations accounted only for 26% of all inpatient 
isolates (282/1057) and the diversity of resistant phe-
notypes was much broader than that from outpatient 
isolates.
654
357
221
189 185 184
162
128
18 12 9 7 3 1
0
200
400
600
In
te
rs
ec
tio
n 
S
iz
e
Cephalosporins_3_4
OXA_any
TEM
CTXM_any
0500100015002000
Set Size
Fig. 3 Association between non-susceptibility to 3rd and 4th generation cephalosporins and combinations of resistance genes blaOXA, blaCTXM 
and blaTEM. Black circles represent non-susceptibility to cephalosporins (3rd/4th gen.) and/or the detection of resistance genes of blaOXA family, 
blaCTXM family or blaTEM. A grey circle indicates that a characteristic was not detected. The vertical bars indicate the number of isolates in the group 
summarized directly below. The horizontal bars indicate the total number of isolates positive for resistance genes of blaOXA family, blaCTXM family, 
for blaTEM or for non-susceptibility to 3rd and 4th generation cephalosporins. An isolate was classified as blaOXA positive if any gene of blaOXA family 
was detected. The same is true for blaCTXM genes. Only isolates that had a known 3rd and 4th generation cephalosporin resistance profile and were 
tested for at least one member of blaOXA family, at least one member of blaCTXM family and blaTEM were included
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Discussion
In this study, very high prevalence of ESBL positivity and 
MDR was found in Enterobacteriaceae family bacteria 
(E. coli, Klebsiella spp. and Enterobacter spp.). Similar 
MDR prevalence has been reported in other studies from 
Nepal, but the ESBL positive prevalence we observed 
(over 50%) is higher than others have reported. For exam-
ple, one study from Nepal found that in community-
acquired infections caused by E. coli, 24% were ESBL 
positive and 78% had MDR [12]. Another hospital-based 
study from Nepal showed that in urine samples, 27% of 
E. coli were ESBL positive and 97% of Enterobacteriaceae 
bacteria (mostly E. coli and Klebsiella spp.) were multi-
drug resistant [13]. For Acinetobacter spp., we report 
over 81% MDR, similar to what others have reported in 
ICUs in Nepal, but the ESBL prevalence we found (< 1% 
in Acinetobacter spp.) is much lower than what has been 
reported (around 12–13%) [15, 16, 29]. In the context of 
South Asia, 79% of Acinetobacter spp., 71% of Klebsiella 
spp. and 54% of E. coli isolated from young infants were 
estimated to be multi-drug resistant strains [19]. ESBL 
positivity was confirmed in 42% of K. pneumoniae and 
33% of E. coli isolated from several hospitals in India [30], 
40% in Enterobacteriaceae isolates from Pakistan [18] 
and 16% in enteric and non-enteric Gram-negative bacilli 
from Bangladesh [31].
To limit the spread of antimicrobial resistant micro-
organisms, to guide clinical care and improve patients’ 
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Fig. 4 Association between MDR and combinations of resistance genes blaOXA, blaCTXM and blaTEM. Black circles represent MDR and/or the 
detection of resistance genes of blaOXA family, blaCTXM family or blaTEM. A grey circle indicates that a characteristic was not detected. The vertical 
bars indicate the number of isolates in the group summarized directly below. The horizontal bars indicate the total number of isolates positive for 
resistance genes of blaOXA family, blaCTXM family, for blaTEM or for MDR phenotype. An isolate was classified as blaOXA positive if any gene of blaOXA 
family was detected. The same is true for blaCTXM genes. Only isolates that had an AMR profile and were tested for at least one member of blaOXA 
family, at least one member of blaCTXM family and blaTEM were included
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outcome, it is essential to have precise knowledge on 
AMR profile of the infecting bacteria prior to start-
ing antimicrobial therapy to select an appropriate drug. 
Antimicrobial sensitivity testing and detection of ESBL 
positivity can be performed by classical phenotypical 
methods such as disc diffusion, which is labour inten-
sive and time consuming. Automated systems exist, but 
their installation, running and maintenance costs are 
often a barrier in low resource settings. Alternatively, 
simple genetic methods such as PCR can detect AMR 
genes rapidly and with high sensitivity [2, 10, 32]. A bet-
ter understanding of the association between phenotype 
and genotype is a prerequisite to evaluate the usefulness 
of genetic detection methods in clinical settings. In this 
study, we assessed the correlation between the detection 
of blaCTXM, blaTEM and blaOXA genes by PCR and ESBL 
positivity or MDR as detected phenotypically by disc 
diffusion.
For E. coli, Enterobacter spp. and Klebsiella spp., the 
resistance genes most frequently detected were blaOXA, 
blaTEM, blaCTXM-1 and blaCTXM-8.This is consistent with 
a study performed in 2012–2013 at Kathmandu Medi-
cal College and Teaching Hospital, in which blaCTXM and 
blaTEM were frequently detected in ESBL positive E. coli 
[14]. A study from Bangladesh reported blaCTXM-1 (51%) 
and blaSHV (27%) to be the most common ESBL genes 
in Klebsiella pneumoniae [17]. In Pakistan and India, 
as in our study, blaOXA, blaTEM and blaCTXM, in addi-
tion to blaSHV were detected to be common AMR genes 
in Enterobacteriaceae isolates [18, 30]. For Acinetobac-
ter spp., blaOXA-51, blaOXA-23 and blaNDM-1were the most 
frequently detected AMR genes, as found by others in 
Nepal, India and Bangladesh [33–35].
The detection of any gene of the blaCTXM family was 
strongly associated with ESBL positivity (OR 14.2, 95% 
CI11.2–18.1), MDR (OR 5.99, 95% CI 4.2–8.6) and resist-
ance to 3rd and 4th generation cephalosporins (OR 14.7, 
95% CI 6.6–38.6). The detection of blaTEM was strongly 
associated with ESBL positivity (OR 2.96, 95% CI 2.5–
3.6) and MDR (OR 1.96, 95% CI 1.4–2.7). An association 
between blaTEM and resistance to 3rd and 4th genera-
tion cephalosporins was suggested by an OR of 1.4, but it 
was not statistically significant (95% CI 0.8–2.4), perhaps 
due to low number of isolates susceptible to 3rd and 4th 
generation cephalosporins. Finally, the detection of any 
gene of the blaOXA family was associated with multi-drug 
resistant phenotype (OR 2.3, 95% CI 1.7–3.1). This sug-
gests that the detection of blaTEM, or any gene of the 
blaCTXM or blaOXA family is an important index for multi-
drug resistant phenotype, and as expected, the detection 
of a blaCTXM family gene or blaTEM indicates a higher 
odds of ESBL positive phenotype. Collectively, this sug-
gests that the detection of key AMR genes by molecular 
methods is an important index for ESBL positivity and 
MDR in bacterial isolates.
In this study, we also described different AMR pat-
terns found in the isolates originating from emergency 
and outpatient wards (outpatients) compared to all other 
wards of the hospital (inpatients), which may reflect dif-
ferent usage of antimicrobials in community compared 
to the hospital. It can be assumed that isolates originat-
ing from outpatients reflect what is circulating in com-
munities. For outpatients, the three most frequent AMR 
combinations accounted for more than half of all isolates. 
Perhaps people contracting community-acquired infec-
tions predominantly self-medicate, which results in expo-
sure to the limited array of antimicrobials that are freely 
available in shops and pharmacies. Only infections that 
are (or have become) resistant to those drugs prompt a 
visit to the hospital. As a result, infections seen in outpa-
tients have similar resistance profile. In contrast, a higher 
diversity of AMR combinations found in inpatients may 
reflect a wider array of antimicrobials available and used 
at hospitals.
Conclusions
MDR along with possession of ESBL and carbapene-
mase associated resistance genes among Gram-negative 
bacilli pose a serious problem in therapeutic manage-
ment of patients. The compromised infection control 
and inadequate antimicrobial usage policies coupled with 
high burden of Gram-negative bacilli possessing trans-
ferable antimicrobial resistance genes in resource lim-
ited settings set out an ideal scenario for the emergence 
and dissemination of multi-drug resistant pathogens. 
In this extensive retrospective study, a high burden of 
multi-drug resistant clinical Gram-negative bacilli pos-
sessing diverse ESBL and carbapenemase resistance bla 
genes were evidenced. Further, our study signifies that 
there is a high probability of Gram-negative bacilli to be 
multi-drug resistant and ESBL positive in case of detec-
tion of any of blaTEM, blaCTXM or blaOXA family genes. 
(See figure on next page.)
Fig. 5 AMR patterns for outpatients and inpatients. AMR patterns are presented for outpatients (emergency and outpatients departments) in (a) 
and for inpatients (all other hospital wards) in (b). Only the 42 most frequent combinations are shown. Black circles represent resistance to the 
antimicrobials groups and/or multidrug resistance (MDR). The vertical bars represent the number of isolates characterized by the AMR pattern 
described under the bar. The horizontal bars indicate the total number of isolates resistant to the different groups, or MDR
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Additionally, the detection of any of the blaCTXM family 
genes highly implies that the Gram-negative bacilli are 
non-susceptible to the extended-spectrum beta-lactam 
antimicrobials.
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